ICH Safety Guidelines:
Revised ICH Safety Guidelines are listed below:
S1A - S1C Carcinogenicity Studies
S1 Rodent Carcinogenicity Studies for Human Pharmaceuticals
S1A Need for Carcinogenicity Studies of Pharmaceuticals
S1B Testing for Carcinogenicity of Pharmaceuticals
S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals
S2 Genotoxicity Studies
S2(R1) Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use
S3A - S3B Toxicokinetics and Pharmacokinetics
S3A Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies S3A Q&As Questions and Answers: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure - Focus on Microsampling
S3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies
S4 Toxicity Testing
S4 Duration of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Toxicity Testing)
S5 Reproductive Toxicology
S5(R2) Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility S5(R3) Revision of S5 Guideline on Detection of Toxicity to Reproduction for Human Pharmaceuticals
S6 Biotechnological Products
S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
S7A - S7B Pharmacology Studies
S7A Safety Pharmacology Studies for Human Pharmaceuticals
S7B The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals
S8 Immunotoxicology Studies
S8 Immunotoxicity Studies for Human Pharmaceuticals
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
S9 Q&As Questions and Answers: Nonclinical Evaluation for Anticancer Pharmaceuticals
S10 Photosafety Evaluation
S10 Photosafety Evaluation of Pharmaceuticals
S11 Nonclinical Safety Testing Cross-cutting Topics
S11 Nonclinical Safety Testing in Support of Development of Paediatric Medicines
Ref:
ICH Safety Guidelines
Revised ICH Safety Guidelines are listed below:
S1A - S1C Carcinogenicity Studies
S1 Rodent Carcinogenicity Studies for Human Pharmaceuticals
S1A Need for Carcinogenicity Studies of Pharmaceuticals
S1B Testing for Carcinogenicity of Pharmaceuticals
S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals
S2 Genotoxicity Studies
S2(R1) Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use
S3A - S3B Toxicokinetics and Pharmacokinetics
S3A Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies S3A Q&As Questions and Answers: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure - Focus on Microsampling
S3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies
S4 Toxicity Testing
S4 Duration of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Toxicity Testing)
S5 Reproductive Toxicology
S5(R2) Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility S5(R3) Revision of S5 Guideline on Detection of Toxicity to Reproduction for Human Pharmaceuticals
S6 Biotechnological Products
S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
S7A - S7B Pharmacology Studies
S7A Safety Pharmacology Studies for Human Pharmaceuticals
S7B The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals
S8 Immunotoxicology Studies
S8 Immunotoxicity Studies for Human Pharmaceuticals
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
S9 Q&As Questions and Answers: Nonclinical Evaluation for Anticancer Pharmaceuticals
S10 Photosafety Evaluation
S10 Photosafety Evaluation of Pharmaceuticals
S11 Nonclinical Safety Testing Cross-cutting Topics
S11 Nonclinical Safety Testing in Support of Development of Paediatric Medicines
Ref:
ICH Safety Guidelines
No comments:
Post a Comment